Inovio Analyst Says Thermo Fisher Deal 'One Solid Step' Toward COVID-19 Vaccine Commercialization

Inovio Pharmaceuticals Inc INO, which has had a legal tussle with its South Korean CDMO, announced Tuesday an agreement with Thermo Fisher Scientific Inc. TMO to manufacture Inovio's DNA COVID-19 vaccine.

The Inovio Analyst: H.C. Wainwright analyst Raghuram Selvaraju reiterated a Neutral rating on Inovio. 

The Inovio Takeaways: The inclusion of Thermo Fisher in the global consortium significantly strengthens Inovio's manufacturing capacity and represents one "solid step" toward potential commercialization of INO-4800 in 2021, Selvaraju said in a Wednesday note.

Along with its existing manufacturing partners Richter-Helm Biologics and Ology Bioscience, Inovio now has the potential to manufacture 100 million doses of INO-4800 in 2021, the analyst said. 

Thermo Fisher is to provide fill and finish of INO-4800 at its commercial facilities in the U.S., he said. 

Inovio is in active discussions with additional manufacturers to join the consortium, Selvaraju said.

Inovio's INO-4800 is slated to enter a Phase 2/3 trial later this month, the analyst said.

INO Price Action: Inovio shares were trading 10.41% higher at $10.61 at last check Wednesday. 

Related Links:

The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechHealth CareReiterationAnalyst RatingsMoversTrading IdeasGeneralH.C. WainwrightRaghuram Selvaraju
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!